首页>投融资
MediWound
上市后再融资
MediWound Ltd.是一个完全垂直整合的生物制药公司,专注于开发、生产并商业化新产品,以满足在严重烧伤、慢性和其他难以愈合伤口及结缔组织疾病等领域的治疗需求。其创新生物医药产品 NexoBrid于2012年12月获得欧洲药品局(即EMA)上市批准,用以去除死亡或受损组织(即焦痂)并处理 局部以及全身的热烧伤(即严重烧伤)。基于其蛋白水解酶专利技术的NexoBrid代表了在烧伤护理中的新模式,且该公司的临床试验已经在统计学意义上说明,病人可以实现无住院、非手术、无额外组织损伤的早期焦痂的快速取出。通过其在德国的全资子公司,该公司于2013年12月在欧盟推出了NexoBrid,目标客户是在烧伤中心和医院烧伤单位进行烧伤治疗的病人。该公司还计划于2014年上半年在美国启动 第3阶段的关键性研究,以向美国食品和药物管理局(即FDA)提出生物制品许可申请(即BLA)。该公司在以色列亚夫涅的总部拥有最先进的、 EMA认证的、符合CGMP的 、无菌药品生产制造工商。而NexoBrid就在此处进行生产。该公司于2000年1月27日在以色列依法注册成立。
基本信息
-
公司全称MediWound Ltd
-
类型生物创新药研发商
-
产业领域药品研发/制造、生物药
-
公司人数51~100人
-
地址42 Hayarkon Street Yavne 8122745 Israel
-
联系电话972-77-9714100
-
邮箱info@mediwound.com
-
成立时间2001-01-01
投融资
-
2024-07-15上市后再融资1500万美元Mölnlycke
-
2023-05-09上市后再融资1000万美元Biomedical Advanced Research and Development Authority
-
2023-02-07增发2750万美元未透露
-
2022-02-17上市后再融资未透露United States Department of Defense
-
2020-03-03上市后再融资550万美元未透露
-
2017-09-19上市后再融资2200万美元未透露
-
2014-03-20上市6510.0万美元未透露
-
2013-06-23未透露1800万美元Clal Biotechnology Industries
- 加载更多
相关投融资企业
捐赠/众筹/授予
igaTx 是一家生物技术公司,开发工程化单体 IgA 中性粒细胞接合器,以释放中性粒细胞对癌症的肿瘤杀伤能力,以及针对传染病的工程化二聚体 IgA 杀伤能力。该公司在工程治疗性 IgA 方面的前沿方法基于 Jeanette Leusen 教授在乌得勒支医学中心(荷兰乌得勒支)进行的开创性工作,并广泛适用于许多不同疾病。
C轮
SiteOne Therapeutics, founded by Stanford University, is a biotechnology company focused on the development of long-acting analgesics, non-norcotic analgecis and diagnostic imaging agents for pain and cancer.In May 2023, SiteOne Therapeutics Inc received a grant for up to $15 million from the National Institute on Drug Abuse.In January 2017, the company raised $15 million in a series B round of financing
A轮
PsiOxus Therapeutics Ltd was formed from the merger of Myotec Therapeutics and Hybrid BioSystems in December 2010. The company is focused on the development of novel therapeutics that address cancer and other clinically unmet diseases.Myotec Therapeutics was a spin-out from Imperial Innovations and was set up to develop technology originated at Imperial College London. It focused on repurposing drugs for the treatment of cachexia, with the intention of out-licensing after completion of phase II studies.In June 2017, the company expanded its operations into a 21,000 sq ft state-of-the-art facility on the Abingdon Science Park in Oxfordshire, UK and a new US facility in Plymouth Meeting near Philadelphia, PA.In April 2012, PsiOxus announced that it would expand into new facilities at the Milton Park in Oxfordshire, UK. The expansion would include a bespoke laboratory for the research and development of novel viral therapeutics; later that month, the facility was opened.By Decem